The 32 references in paper T. Rudenko E., M. Vasilyeva P., I. Kutyrina M., N. Solomakhina I., Т. Руденко Е., М. Васильева П., И. Кутырина М., Н. Соломахина И. (2015) “Сывороточная концентрация цистатина С и мочевой кислоты у пациентов с хронической болезнью почек и гипертрофией левого желудочка сердца // Cystatin C and uric acid levels in detecting left ventricular hypertrophy in patients with chronic kidney disease” / spz:neicon:nefr:y:2015:i:2:p:68-75

1
Ronco C, Haapio M, House A et al. Cardiorenal syndrome. JACC 2008; 52: 1527-1539
(check this in PDF content)
2
Мухин НА, Моисеев ВС. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн РАМН 2003; 11: 50-55
(check this in PDF content)
3
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15
(check this in PDF content)
4
Шутов АМ, Серов ВА. Кардиоренальный и ренокардиальный синдромы. Нефрология 2009; 13 (4):59-63
(check this in PDF content)
5
Гарсиа-Донаире ЖА, Руилопе ЛМ. Кардио-васкулярноренальные связи в кардиоренальном континууме. Нефрология 2013; 17 (1):11-19
(check this in PDF content)
6
Каюков ИГ, Смирнов АВ, Эммануэль ВЛ. Цистатин С в современной медицине. Нефрология 2012; 16(1): 22-39
(check this in PDF content)
7
Вельков ВВ. Цистатин С: новые возможности и новые задачи для лабораторной диагностики. Клиниколабораторный консилиум 2010; 05(36): 23-31
(check this in PDF content)
8
Fassett RG, Venuthurupalli SK, Gobe GC, et el. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806–821
(check this in PDF content)
9
Пролетов ЯЮ, Саганова ЕС, Галкина ОВ и др. Роль некоторых биомаркеров в оценке характера хронического повреждения почек у пациентов с первичными гломерулопатиями. Нефрология 2013; 17 (1):60-69
(check this in PDF content)
10
Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173–179
(check this in PDF content)
11
Kiyosue A, Hirata Y, Ando J et al. Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J 2010; 74: 2441–2447
(check this in PDF content)
12
Taglieri1 N, Koenig W, Kaski1 JC. Cystatin C and Cardiovascular Risk. Clinical Chemistry 2009; 55(11): 1932-1943
(check this in PDF content)
13
Reese PP, Feldman HI. More evidence that cystatin C predicts mortality better than creatinine. JASN 2009; 20: 2085-2092
(check this in PDF content)
14
Золотухин ПВ, Чмыхало ВК, Макаренко МС и др. Положительный контур мочевой кислоты, гомоцистеина, NOX и XOR: нефрологические аспекты. Нефрология 2014; 18(5): 16-22
(check this in PDF content)
15
Jonasson T, Ohlin AK, Gottsäter A, et al. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease – a prospective randomized study of vitamin supplementation. Clin Chem Lab Med 2005; 43: 628–634
(check this in PDF content)
16
Latif Walead, Karaboyas A, Tong L. Uric Acid Levels and All-Cause and Cardiovascular Mortality in the Hemodialysis Population. Clin J Am Soc Nephrol 2011; 6(10): 2470–2477
(check this in PDF content)
17
Liu WC, Hung CC, Chen SC et al. Association of Hyperuricemia with Renal Outcomes, Cardiovascular Disease, and Mortality. Clin J Am Soc Nephrol 2012;7(4):541-548
(check this in PDF content)
18
Madero M, Sarnak MJ, Wang X, et al. Uric acid and longterm outcomes in CKD. Am J Kidney Dis 2009; 53: 796–803
(check this in PDF content)
19
Patel PC, Ayers CR, Murphy SA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009; 2(2): 98-104
(check this in PDF content)
20
Xin Li, Hang Zhu, Peng Li, el at. Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy. J Geriatr Cardiol 2013; 10(3): 286–290
(check this in PDF content)
21
Kestenbaum B, Rudser KD, de B I, et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 2008;148: 501-508
(check this in PDF content)
22
Cheng XW, Obata K, Kuzuya M et al. Elastolytic cathepsin induction/ activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006; 48: 979–987
(check this in PDF content)
23
Sam F, Siwik DA. Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure. Hypertension 2006; 48 (5): 830–831.
(check this in PDF content)
24
Xie L, Terrand J, Xu B et al. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 2010; 87: 628–635
(check this in PDF content)
25
Shlipak MG, Katz R, Cushman M, Sarnak MJ et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005;118:1416.e25-1416.e31
(check this in PDF content)
26
Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 2007; 22:1087-1092
(check this in PDF content)
27
Sánchez-Lozada LG, Tapia E, Santamaría J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67(1): 237–247
(check this in PDF content)
28
Щербак АВ, Козловская ЛВ, Бобкова ИН., Балкаров И.М. Гиперурикемия и проблема хронической болезни почек. Тер арх 3013; 6: 10-16
(check this in PDF content)
29
Sandra N Ofori, Osaretin J Odia. Serum uric acid and target organ damage in essential hypertension. Vascular Health and Risk Management 2014; 10: 253–261
(check this in PDF content)
30
Мухин НА, Фомин ВВ, Лебедева МВ. Гиперурикемия как компонент кардиоренального синдрома. Тер арх 2011; 83(6): 5-13
(check this in PDF content)
31
Ge C, Ren F, Lu S, et al. Clinical Prognostic Significance of Plasma Cystatin C Levels among Patients With Acute Coronary Syndrome. Clin Cardiol 2009; 32 (11): 644-648
(check this in PDF content)
32
Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269–275 Авторы заявляют об отсутствии конфликта
(check this in PDF content)